Evaluation the Efficacy of CURCUDEN 35 in Patients with COVID-19

Evaluation the Efficacy of CURCUDEN in Patients with COVID-19 Pneumonia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170128032241N3

Enrollment

Registered

2020-08-17

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19 pneumonia Disease. covid-19 pneumonia

Interventions

Intervention 1: Intervention group: Patients with covid-19 who use curcumin in addition to first-line drugs during treatment. Intervention group receive two capsules of CURCUDEN® every 12 hours in add

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Virological diagnosis of SARS-CoV-2 infection by RT-PCR Positive imaging findings: Condensation, Grand Glass opacity or bilateral pulmonary infiltration on CT scan or Chest X-ray Need to get extra oxygen to maintain SO2> 94% or PaO2 / FiO2> 300

Exclusion criteria

Exclusion criteria: Age less than 18 years The patient has septic shock Pregnancy and lactation The patient is intubated and under mechanical ventilation The patient was admitted to the ICU Having an allergy to curcumin

Design outcomes

Primary

Measure	Time frame
1- Evaluation of clinical variables involved in patients' recovery including mechanical ventilation. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Spirometry test.;2- Organ failure and comparison of these results in the two groups of treatment and control. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Examination and registration of clinical signs.;3- Mortality and comparison of these results in the two groups of treatment and control. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Record vital signs.;4- The length of hospital stay and comparison of these results in the treatment and controlgroups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Evaluation of the length of hospital stay.;5- Length of ICU hospitalization and comparison of these results in the treatment and controlgroups. Timepoint: On days 1 and 5 of the start of treatment. Method of measurement: Check the period of hospitalization in the ICU.;6- Receiving oxygen and comparing these results in the treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Nursing information on the use of oxygen capsules.;7- The length of the negative period of PCR test and comparison of these results in thetreatment and control groups. Timepoint: On days 1 and 14 of the start of treatment. Method of measurement: Polymerase Chain Reaction.;8- Comparison of interleukin-6 levels in the treatment and control groups. Timepoint: On days 1 and 14 of the start of treatment. Method of measurement: Polymerase Chain Reaction.;9- Comparison of patients' ferritin levels in treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Blood biochemical test.;10- Comparison of patients' CRP levels in treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of	—

Measure

Time frame

1- Evaluation of clinical variables involved in patients' recovery including mechanical ventilation. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Spirometry test.;2- Organ failure and comparison of these results in the two groups of treatment and control. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Examination and registration of clinical signs.;3- Mortality and comparison of these results in the two groups of treatment and control. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Record vital signs.;4- The length of hospital stay and comparison of these results in the treatment and controlgroups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Evaluation of the length of hospital stay.;5- Length of ICU hospitalization and comparison of these results in the treatment and controlgroups. Timepoint: On days 1 and 5 of the start of treatment. Method of measurement: Check the period of hospitalization in the ICU.;6- Receiving oxygen and comparing these results in the treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Nursing information on the use of oxygen capsules.;7- The length of the negative period of PCR test and comparison of these results in thetreatment and control groups. Timepoint: On days 1 and 14 of the start of treatment. Method of measurement: Polymerase Chain Reaction.;8- Comparison of interleukin-6 levels in the treatment and control groups. Timepoint: On days 1 and 14 of the start of treatment. Method of measurement: Polymerase Chain Reaction.;9- Comparison of patients' ferritin levels in treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of measurement: Blood biochemical test.;10- Comparison of patients' CRP levels in treatment and control groups. Timepoint: On days 1, 5 and 14 of the start of treatment. Method of

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Azodi

Alborz Nanomed Tech. Co.

mohajeri_maryam@yahoo.com+98 21 6605 7174

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026